- Home
- ARMN vs CRMD Comparison
ARMN vs CRMD Comparison
Compare ARMN & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- CRMD
- Stock Information
- Founded
- ARMN 1992
- CRMD 2006
- Country
- ARMN Canada
- CRMD United States
- Employees
- ARMN N/A
- CRMD N/A
- Industry
- ARMN
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- ARMN
- CRMD Health Care
- Exchange
- ARMN Nasdaq
- CRMD Nasdaq
- Market Cap
- ARMN 769.7M
- CRMD 645.0M
- IPO Year
- ARMN N/A
- CRMD 2010
- Fundamental
- Price
- ARMN $4.97
- CRMD $6.10
- Analyst Decision
- ARMN
- CRMD Strong Buy
- Analyst Count
- ARMN 0
- CRMD 7
- Target Price
- ARMN N/A
- CRMD $15.14
- AVG Volume (30 Days)
- ARMN 853.8K
- CRMD 2.2M
- Earning Date
- ARMN 05-13-2025
- CRMD 05-08-2025
- Dividend Yield
- ARMN N/A
- CRMD N/A
- EPS Growth
- ARMN 77.15
- CRMD N/A
- EPS
- ARMN 0.14
- CRMD N/A
- Revenue
- ARMN $510,604,000.00
- CRMD $43,472,170.00
- Revenue This Year
- ARMN $49.45
- CRMD $192.92
- Revenue Next Year
- ARMN $4.63
- CRMD $56.23
- P/E Ratio
- ARMN $34.83
- CRMD N/A
- Revenue Growth
- ARMN 14.06
- CRMD N/A
- 52 Week Low
- ARMN $3.29
- CRMD $3.61
- 52 Week High
- ARMN $5.16
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- ARMN 69.07
- CRMD 24.77
- Support Level
- ARMN $4.50
- CRMD $5.88
- Resistance Level
- ARMN $4.88
- CRMD $6.35
- Average True Range (ATR)
- ARMN 0.21
- CRMD 0.61
- MACD
- ARMN 0.04
- CRMD -0.40
- Stochastic Oscillator
- ARMN 86.09
- CRMD 4.04
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development and operation of gold properties in Colombia, Guyana and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, Toroparu Project in Guyana and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.